Neurizon Therapeutics has inked an exclusive global licensing deal with New York Stock Exchange-listed Elanco Animal Health ...

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has ...

Oryx invests in the minerals value chain, targeting critical and strategic minerals assets in favorable jurisdictions ...

Elanco (ELAN) stock in focus as Australia's Neurizon Therapeutics (PAAFF) enters into a licensing deal with the company for ...

Global demand for culturally rich audio is turning traditional Scottish music into a sought-after asset in film, advertising, and digital storytelling ...

Special Report: Neurizon Therapeutics has inked an exclusive global licensing deal with New York Stock Exchange-listed Elanco Animal Health Incorporated and affiliates for monepantel, the active ...

The Confederation of Indian Industry (CII) advocates for a comprehensive revamp of India's critical minerals policy, pushing ...

Today's rally followed Glenmark's Thursday announcement that its innovation arm, Ichnos Glenmark Innovation (IGI), has ...

Businesses say the rising music licensing costs have become overwhelming, and some question whether it’s even worth playing ...

Pharma major Lupin has entered into a strategic licensing and supply agreement with Czech-based Zentiva to commercialize its ...